NEW YORK, NY / ACCESSWIRE / July 16, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the lead plaintiff deadlines listed below to petition the court, and those interested in their eligibility are encouraged to contact the firm. There will be no cost or obligation to you.
Eros International Plc (EROS)
Lawsuit on behalf of: investors who purchased July 28, 2017 - June 5, 2019
Lead Plaintiff Deadline : August 20, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/eros-international-plc-loss-form?prid=2429&wire=1
According to the filed complaint, during the class period, Eros International Plc made materially false and/or misleading statements and/or failed to disclose that: (1) Eros and its executives engaged in a scheme to use related-party
transactions to fabricate receivables that they reported in Eros’s public financial disclosures; (2) because of this scheme, Eros’s financial position was weaker than what the Company disclosed; (3) consequently, the Company’s Indian subsidiary, Eros International Media Ltd (“EIML”), missed loan payments and had its credit
downgraded; and (4) due to the foregoing, Defendants’ statements about Eros’s receivables, business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Teva Pharmaceutical Industries Ltd. (TEVA)
Lawsuit on behalf of: investors who purchased on behalf of all persons or entities who purchased or otherwise acquired Teva American Depositary Shares (“ADS”) between August 4, 2017 and May 10, 2019
Lead Plaintiff Deadline : August 23, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/teva-pharmaceutical-industries-ltd-loss-form?prid=2429&wire=1
According to the filed complaint, (i) contrary to its public denials, Teva had in fact engaged in a vast, industry-wide price-fixing scheme and other collusive misconduct since at least 2012; (ii) Teva was not only a participant, but the company at the heart of the anticompetitive scheme; and (iii) several Teva employees had such deep involvement in the scheme that they would ultimately be named personally as defendants in a sweeping civil enforcement action filed by the AGs of virtually every state in the nation.
Fred's, Inc. (FRED)
Lawsuit on behalf of: investors who purchased December 20, 2016 - June 28, 2017
Lead Plaintiff Deadline : August 27, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/freds-inc-loss-form?prid=2429&wire=1
According to the filed complaint, defendants made numerous materially false and misleading statements concerning the level of regulatory risk faced by the Original Merger and the Revised Merger which would ultimately cause the termination of the Fred’s Asset Purchase Agreement. Specifically, Defendants made false and/or misleading statements: (i) downplaying or disputing contrary reports from journalists signaling regulatory turbulence in closing the merger; (ii) representing that inside knowledge of the FTC gave confidence that the deal would close.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: